Möchten Sie immer auf dem neuesten Stand bleiben?

Company announcement – No. 20/ 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 19/ 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, April 9, 2021 – Zealand Pharma A/S...

Company announcement – No. 18/ 2021 Total number of shares and voting rights in Zealand Pharma at March 31, 2021 Copenhagen, DK and Boston, MA, U.S., March 31, 2021 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 17 / 2021Zealand Pharma to participate in upcoming investor conferencesCopenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....

Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes Zegalogue will be...

Company announcement – No. 15 / 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 14 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, March 19, 2021 –...

Company Announcement – No. 13 / 2021 Zealand Pharma convenes its Annual General Meeting 2021 Copenhagen, 16 March, 2021 – Zealand Pharma A/S (the "Company") convenes the Annual...

Company announcement – No. 12 / 2021 Zealand Pharma: on Track for Potential First Product Launch and Establishing Commercial Operations in the United States Full Year Results for 2020 ...

Company announcement – No. 11/ 2021 Total number of shares and voting rights in Zealand Pharma at February 28, 2021 Copenhagen, March 9, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no....